Sarcopenic Obesity in Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a public health epidemic that is projected to double over the next two decades. Despite the high prevalence of HFpEF, there are currently no FDA approved therapies for health-related outcomes in this clinical syndrome making it one the greate...
Main Authors: | Danielle L. Kirkman, Natalie Bohmke, Hayley E. Billingsley, Salvatore Carbone |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-09-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fendo.2020.558271/full |
Similar Items
-
Differential Response to Interleukin‐1 Blockade With Anakinra on Cardiorespiratory Fitness in Patients With Heart Failure With Preserved Ejection Fraction Stratified According to Left Ventricular Ejection Fraction
by: Michele Golino, et al.
Published: (2023-09-01) -
Diastolic Ventricular Interaction in Heart Failure With Preserved Ejection Fraction
by: Sathish K. Parasuraman, et al.
Published: (2019-04-01) -
Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross‐over trial
by: Arno A. van deBovenkamp, et al.
Published: (2023-10-01) -
Soluble ST2 in Heart Failure With Preserved Ejection Fraction
by: Omar F. AbouEzzeddine, et al.
Published: (2017-02-01) -
The role of cardiac magnetic resonance imaging in the assessment of heart failure with preserved ejection fraction
by: Clement Lau, et al.
Published: (2022-07-01)